BACKGROUND: Overt thyroid dysfunction has been associated with adverse obstetric outcomes. However, less is known regarding subclinical hypothyroidism or thyroid autoimmunity and their relationship to pregnancy complications. OBJECTIVE: The purpose of this study was to examine the association between prepregnancy antiethyroid antibodies and subclinical hypothyroidism and preterm delivery, gestational diabetes mellitus, and preeclampsia. STUDY DESIGN: We conducted a secondary analysis of a prospective cohort of 18-to 40-year-old women with 1e2 previous pregnancy losses (n¼1193) who participated in a multicenter randomized, placebocontrolled trial of low-dose aspirin. Prepregnancy levels of thyroidstimulating hormone, free thyroxine, thyroglobulin antibody, and thyroid peroxidase antibody were measured. Relative risks and 95% confidence intervals were estimated with the use of generalized linear models with adjustment for age and body mass index. RESULTS: Among women with an ongoing pregnancy of >20 weeks estimated gestational age, there was no association between prepregnancy thyroid-stimulating hormone level (>2.5 vs 2.5 mIU/L) and preterm delivery (adjusted relative risk, 0.77; 95% confidence interval,
disease complicates approximately 4% of all pregnancies. 1 Overt hypothyroidism has been linked to various pregnancy complications such as preeclampsia, gestational diabetes (GDM), and preterm delivery (PTD). 2, 3 These adverse pregnancy outcomes contribute a significant burden on families and the healthcare system and have important implications for the future health of the child. However, it is unclear whether less severe forms of thyroid disease, specifically subclinical hypothyroidism (SCH), are also linked to obstetric complications.
SCH is defined as an elevated thyroid-stimulating hormone (TSH) level with normal thyroxine (fT4) 4 and is the most common form of thyroid dysfunction in pregnancy. 5 Although several studies have evaluated the relationship between SCH in pregnancy and various adverse pregnancy outcomes, results have been conflicting. [5] [6] [7] [8] [9] Previous studies have been limited by the assessment of thyroid function during early pregnancy, as opposed to preconception when alterations to TSH can occur as the result of the presence of human chorionic gonadotropin and other hormone changes. 10 Thyroid autoimmunity, which is characterized by the presence of thyroid autoantibodies, is also common and has been associated variably with adverse pregnancy outcomes. 5, 11 In 2011, the American Thyroid Association recommended a TSH level of <2.5 mIU/L to be the ideal in early pregnancy. 1 None of the studies referenced earlier, however, examined obstetric outcomes in women with TSH of <2.5 vs !2.5 mIU/L. Furthermore, studies that evaluate the relationship between preconception thyroid levels and pregnancy outcomes are lacking. Thus, our objective was to determine the association between prepregnancy antiethyroid antibodies, SCH, and adverse obstetric outcomes that included PTD, preeclampsia, and GDM.
Materials and Methods
This was a secondary prospective cohort analysis from the Effects of Aspirin in Gestation and Reproduction (EAGeR) trial. The EAGeR trial was a multicenter, double-blind, randomized, placebocontrolled trial that examined the effect of low-dose aspirin on live birth. 12, 13 Women (n¼1228) with a history of 1e2 previous pregnancy losses who were attempting pregnancy were recruited from 4 US medical centers from 2007e2011. A detailed description of the study design and methods has been published. 12 Institutional Review Board authorization was obtained at the data coordinating center and at all clinical centers; each participant provided written informed consent. Patient safety was monitored by a Data Safety and Monitoring Board, and the trial was registered with ClinicalTrials. gov, number NCT00467363.
Study design and population
Participants were women who were 18e40 years old with regular menstrual cycles (21e42 days in length) who were actively attempting to conceive. Although they had a history of 1e2 confirmed pregnancy losses, they did not have diagnosed infertility, pelvic inflammatory disease, tubal occlusion, endometriosis, anovulation, uterine abnormality, polycystic ovarian syndrome, or any major medical disorder. 12 Women in the study were observed through 6 cycles attempting pregnancy. If they did not conceive in 6 cycles or experienced a second periconception loss during the study, their study participation was discontinued. If they became pregnant, they were observed prospectively throughout the pregnancy and delivery. Fertility monitors (Clearblue Easy Fertility Monitor; Inverness Medical, Waltham, MA) were used to assist with the scheduling of study visits and timing of intercourse.
Thyroid function assessment
Preconception TSH, fT4, thyroglobulin antibody (anti-TG), and thyroid peroxidase antibody (anti-TPO) levels were measured in serum that was collected at a baseline visit before conception. Samples were stored at e80 C after collection until the time of assay. TSH was measured by the TSH reagent sandwich immunoassay method (Roche Diagnostics, Indianapolis, IN). The reference range was 0.4e5 mIU/L, and the interassay laboratory coefficients of variation were 2.1% at 1.596 mIU/L and 2.9% at 9.037 mIU/L. FT4 level was measured with the use of an fT4 reagent/ competitive immunoassay (Roche Diagnostics), with a reference range of 0.7e1.85 ng/dL. Anti-TG antibody levels were measured with a TSH reagent sandwich immunoassay (Roche Diagnostics); the interassay coefficients of variations were 7.2% at 91.4 IU/mL and 6.7% at 171 IU/mL. Anti-TPO levels
were measured with an anti-TPO reagent competitive immunoassay (Roche Diagnostics); the interassay coefficients of variations were 17% at 31.5 IU/mL and 11.9% at 76.13 IU/mL. Results for anti-TG antibody were considered positive if the anti-TG level was !115 IU/mL; results were considered positive if the anti-TPO level was !35 IU/mL, according to the reference ranges at our laboratory.
Outcome measures
Reproductive, medical, and obstetric histories were obtained at baseline by questionnaire and from medical record abstraction. A clinically confirmed pregnancy was defined as evidence of a continuing intrauterine pregnancy with ultrasound examination at 6e7 weeks gestation. Gestational age was determined by an ultrasound examination that was conducted in early pregnancy (mean, 6.9 weeks gestation) for 97% of clinically confirmed pregnancies (697/ 720) among women who completed the trial; for the remaining 3% of pregnancies(23/720), gestational age was determined with the use of menstrual cycle dating from home-based fertility monitors that had been provided by the study. The dates and details of pregnancy outcomes were assessed by postpartum phone interview and through medical record abstraction by trained research staff.
Primary outcomes for this analysis included PTD, GDM, and preeclampsia. PTD was defined as delivery between 20 weeks zero days and 36 weeks 6 days gestation. Cases of PTD were identified prospectively during the study and underwent further review of abstracted medical records by a maternal-fetal medicine physician to vet and categorize the outcome as spontaneous, medically indicated, or a preterm birth of uncertain indication. Spontaneous preterm birth was defined as any preterm birth preceded by spontaneous labor (cervical change or !4-cm cervical dilation in the presence of contractions), preterm premature rupture of membranes, or both. Medically indicated preterm birth was defined as any preterm birth not classified as spontaneous preterm birth for which at least 1 medical indication for delivery was noted in the medical record. In this cohort of patients, the major indication for medical delivery was preeclampsia. The overall number of patients with medically indicated preterm birth was small (n¼28). Of these, 11 cases (39%) were related to preeclampsia. Other indications included placenta previa/ abruption, preterm labor, chorioamnionitis, and nonreassuring fetal heart rate tracing.
The remaining preterm births were categorized as preterm birth of uncertain indication. Physicians who provided prenatal care to patients made a diagnosis of preeclampsia or GDM based on standard clinical and laboratory criteria. Trained EAGeR research staff abstracted these diagnoses from participants' delivery records.
Statistical analysis
Women with an abnormal fT4 level (n¼12) or whose fT4 level was not recorded (n¼23) were excluded. The remaining participants were categorized into 2 groups based on TSH level: TSH <2.5 or !2.5 mIU/L. Although SCH is defined most often as TSH above the normal range (4.5e5.0 mIU/L) with a normal fT4 level, 14 the National Academy of Clinical Biochemistry found that 95% of patients without any symptoms of thyroid dysfunction actually had a TSH level <2.5 mIU/L. We also evaluated participants for the presence or absence of anti-TG and/or anti-TPO antibody. If women were positive for at least 1 antibody, they were included in the thyroid autoimmunity group. Descriptive statistics were used to compare characteristics between groups with the use of Fisher's exact test and ttests where appropriate. Risk ratios (RR) and 95% confidence intervals (CI) for PTD, GDM, and preeclampsia by TSH level (<2.5 or !2.5 mIU/L) and by thyroid autoimmunity status were estimated with the use of log-binomial regression that was adjusted for age and body mass index. We also evaluated pregnancy outcomes in women with thyroid autoimmunity that was stratified by TSH level.
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Because pregnancy outcomes are conditional on becoming pregnant, we restricted our analysis to women who had an ongoing pregnancy of >20 weeks estimated gestational age. As such, we used inverse probability weights to control for potential selection bias that was introduced by restricting the analytical cohort because low-dose aspirin treatment was shown to be associated with the probability of pregnancy among women with a single recent loss. 13, 15, 16 Of note, low-dose aspirin treatment was not associated with GDM, PTD, or preeclampsia, and we also did not observe associations between thyroid exposures and pregnancy loss or fecundity. 17 Weights were based on factors that were associated with becoming pregnant, which included maternal age, parity, marital status, number of previous losses, and treatment assignment. Weighted logbinomial regression was used to estimate RRs and 95% CIs. When evaluating PTD, we also stratified by indication (spontaneous vs medicallyindicated). The number of cases was too low to estimate the RR in some models; therefore, odds ratio (OR) is reported in those instances. Analyses were conducted in SAS software (version 9.4; SAS Institute, Cary, NC).
Results
There were no differences in age, race, and education level in participants with TSH levels of <2.5 mIU/L compared with those with a TSH level of !2.5 mIU/L. Women with a TSH level of !2.5 mIU/L had a higher body mass index and were more often nulliparous compared with women with lower TSH (Table 1) . Women with positive tests for antithyroid antibodies were similar in age and body mass index compared with those women who tested negative. Of the 1018 women without thyroid antibodies, 962 were non-Hispanic white (94.5%), compared with 98.2% non-Hispanic white among women with thyroid antibodies (P¼.04). There was no difference in previous number of live births or pregnancies between groups.
Among women who became pregnant during the study with an ongoing pregnancy >20 weeks gestation, there was no increased risk of PTD (RR, 078; 95% CI, 0.41e1.48), GDM (OR, 1.27; 95% CI, 0.50e3.20), or preeclampsia (OR, 1.16; 95% CI, 0.63e2.15) in women with TSH levels of <2.5 mIU/L vs those with TSH levels of !2.5 mIU/L, either before or after adjustment for potential confounders (Table 2) . Similarly, antithyroid antibodies also were not associated with any of these adverse obstetric outcomes. We further explored whether any differences were noted when we stratified by indication for PTD (spontaneous vs medically indicated), and found no differences.
We also evaluated obstetric outcomes in the cohort of women with both SCH (TSH !2.5 mIU/L) and thyroid autoimmunity (n¼45) because this cohort may be at elevated risk. However, the combination of these 2 assay results was not associated with PTD (OR, 0.77; 95% CI, 0.19e3.13), GDM (RR, 3.24; 95% CI, 0.30e34.55), or preeclampsia (RR, 1.53, 95% CI, 0.38e6.09; Table 3 ).
Comment
SCH and thyroid antibodies were not associated with adverse pregnancy complications among healthy fecund women with an ongoing pregnancy of >20 weeks estimated gestational age. Furthermore, among women with thyroid autoimmunity, there were no differences in PTD, preeclampsia, or GDM even when we stratified by TSH level. These results support current recommendations that low-risk asymptomatic women should not be screened routinely for thyroid dysfunction or autoimmunity.
Previous research on SCH has explored a variety of adverse pregnancy outcomes with inconsistent results. In part, this may be due to varied definitions of SCH among studies. Our results for PTD are in agreement with findings from a recent systematic review and metaanalysis 18 that reported no relationship between PTD and SCH, although an increased risk of PTD was Original Research OBSTETRICS ajog.org noted among women with overt hypothyroidism in that study.
Although available data regarding SCH and preeclampsia are mixed, our results are consistent with a previous retrospective study and metaanalysis that also showed no difference in rates of preeclampsia 6 or gestational hypertension in relation to SCH. 5 An association between SCH and severe preeclampsia (but not gestational hypertension or mild/moderate Association between thyroid autoimmunity and pregnancy outcomes among women with elevated thyroid-stimulating hormone levels ( ‡2.5 mIU/L)
Variable Model
Antithyroid antibodies among women with thyroid-stimulating hormone levels at !2. a Models restricted to women who had an ongoing pregnancy >20 weeks, with inverse probability weights used to control for potential selection bias introduced by restricting to women who achieved pregnancy; weights were based on factors associated with becoming pregnancy, which included age, parity, marital status, number of previous losses, and treatment assignment; weighted logbinomial regression was used to estimate risk ratios and 95% confidence intervals; b Relative risk (95% confidence interval); c Odds ratio (95% confidence interval).
Plowden et al. Thyroid-stimulating hormone and pregnancy outcomes. Am J Obstet Gynecol 2017. a Adjusted for age and body mass index; b Odds ratio used when relative risks would not converge. Models restricted to women who had an ongoing pregnancy >20 weeks gestation; inverse probability weights were used to control for potential selection bias that was introduced by restriction to women who achieved pregnancy. Weights were based on factors associated with becoming pregnant, which included age, parity, marital status, number of previous losses, and treatment assignment. Weighted log-binomial regression was used to estimate risk ratios and 95% confidence intervals. Plowden et al. Thyroid-stimulating hormone and pregnancy outcomes. Am J Obstet Gynecol 2017.
ajog.org OBSTETRICS Original Research preeclampsia) was reported in 1 large study; however, it is of note that SCH was defined as TSH level >4.13 mIU/L, 8 because the results are not directly comparable with our study. Our findings also differ from those of a large Chinese cohort that observed a link between SCH and gestational hypertension. 7 However, their results were not adjusted for body mass index, which may have confounded their findings, and they did not examine preeclampsia as an outcome. 7 In contrast, overt hypothyroidism has been associated with severe preeclampsia [19] [20] [21] and adverse cardiovascular effects, 20, 22, 23 which in turn may be associated with vascular-related pregnancy complications.
Our findings are also in agreement with several investigations of SCH and GDM. Many groups found no association between SCH and GDM, including 2 recent cohort studies. 7, 9 A metaanalysis that examined SCH and pregnancy outcomes also did not detect a link between GDM and SCH (OR, 1.38; 95% CI, 0.97e1.96). 5 Here, we extend these findings that confirm no relationship between SCH and GDM, even with thyroid function measured before pregnancy.
Studies regarding thyroid autoimmunity and pregnancy complications also have yielded mixed results. In this study, we found no difference in PTD, GDM, or preeclampsia among women with thyroid autoimmunity, even among those with an additional finding of SCH. Our results are consistent with several groups who also found no relationship between thyroid antibodies and GDM and preeclampsia; however, these studies found a positive relationship between these antibodies and PTD, 11, [24] [25] [26] which is in contrast to our study. Of note, in 1 of these studies, an association was observed only with the outcome of very preterm birth (<34 weeks gestation), and no adjustments for potential confounders were made. 25 However, anti-TPO positivity was associated with PTD in other studies, which included a recent metaanalysis that adjusted for relevant confounding factors, 11, 24, 26 although some of the previous studies assessed for the presence of only TPO antibodies or used differing definitions of positive antibody status. These differences in study design may account for some of the differences in findings among studies.
This study has several strengths. First, the original trial was prospective, which allowed for preconception assessment of fT4, TSH, and thyroid antibody levels; thus, the assessment of thyroid function was not affected by changes in thyroid function during pregnancy. An important difference between previous work and the current study is our assessment of thyroid function before pregnancy. Because thyroid function is known to change during early pregnancy, this could have important implications for the interpretation of these findings. 10 Furthermore, we were able to evaluate the clinical utility of using a cut point of TSH !2.5 mIU/L. Our results extend previous work by using preconception measurements and exploring the association with stricter and more common definition of SCH. We were also able to adjust for potential confounders in our analyses. Moreover, all outcomes were assessed prospectively; our population was comprised of young, healthy women with a history of pregnancy loss. As such, these results are generalizable to a large population of women. Additionally, the original trial had a high compliance rate; most of the women completed the study follow up (88%). There are some limitations to our study as well. We had a small number of adverse outcomes that made our ability to detect small differences somewhat limited. Additionally, most of this population consisted of white, middle-class, well-educated women, which may limit generalizability.
In conclusion, we found no relationship between PTD, GDM, or preeclampsia and preconception SCH and thyroid autoimmunity, which was defined as the presence of either anti-TPO or anti-TG antibodies, among women with proven fecundity. To date, the American College of Obstetricians and Gynecologist does not recommend screening for TSH or antithyroid antibodies in low-risk, asymptomatic patients; our data support this guideline.
These findings can offer reassurance to women with SCH or thyroid autoimmunity and their healthcare providers.
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